GlaxoSmithKline Race For New Discoveries |
|
|
|
|
Written by VaccineRx Staff
|
|
Wednesday, 04 June 2008 |
|
GlaxoSmithKline (GSK) and the Immune Disease Institute, Boston (IDI)
today announced a five year collaboration worth $25 million to build a
unique partnership in immunoinflammation research.
The
collaboration aims to combine IDIs world-class immunological expertise
with GSKs pharmaceutical capabilities within a competitive framework.
The partnership will be pioneering in the way it allows researchers at
both institutions to develop joint grant proposals in targeted areas of
research under an innovative and competitive Alliance Research grant
program. In addition to the substantial scientific benefits brought by
a long-term synergy with world class immunologists, GSK will receive an
exclusive Right of First Negotiation for a substantial portion of the
new technologies discovered and disclosed by IDI scientists during the
term of the agreement. The research term for the collaboration is five
years and will be anchored through GSKs Immuno-Inflammation Centre of
Excellence in Drug Discovery (II CEDD).
Commenting
on the collaboration, Jose Carlos Gutierrez-Ramos, Ph.D., Senior Vice
President and head of the Immuno-Inflammation Center of Excellence for
Drug Discovery of GSK, stated GSK is committed to becoming a world
leader within 3 years in drug discovery of immuno-inflammation. We are
tremendously excited that we are able to work with IDI scientists, and
share their passion, innovation and ground-breaking technologies. This
agreement fits perfectly with our strategy to pursue scientific
excellence and technologies both internally and externally. The best
science coming from IDI and the best drug discovery capabilities from
GSK will produce transformative medicines that will change patients
lives.
The IDI scientists are
extremely excited about this tremendous opportunity to collaborate with
scientists at GSK, said Frederick Alt, Ph.D, IDIs Scientific
Director. This unique scientific alliance should significantly enhance
our efforts to push forward with ground-breaking research in immunology
and inflammation and, in particular, it should enhance our ability to
translate basic discoveries into the clinical setting.
Tags:
Click to add your tags...,
| Comments () >> |
 |
| Write comment |
You must be logged in to a comment. Please register if you do not have an account yet. |
|